|MDACC Study No:||2012-0822 (clinicaltrials.gov NCT No: NCT01751308)|
|Title:||A Phase I -2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric|
Patients with Refractory Solid Tumors including Tumors of the Central Nervous
|Principal Investigator:||Cynthia E. Herzog|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of cabazitaxel that can be given to children with refractory or recurrent solid
tumors. Researchers also want to learn about the safety of the drug and the
amount of study drug in the body at different time points.
This is the first study using cabazitaxel in children.
Cabazitaxel is designed to interfere with the growth of cancer cells by
stopping cell division.